Research and Development

Pipeline

Argenta's development pipeline comprises:

1. ADC4022 - a potential anti-inflammatory treatment for COPD. It is the group's most advanced compound and is currently being tested in a Phase IIa proof of concept clinical trial. ADC4022 is a proprietary combination of inhaled theophylline and budesonide that has the potential to render COPD and steroid-insensitive asthma responsive to steroid therapies. The group owns all rights to this programme.


2. ADC3322 - an inhaled anti-inflammatory compound for the treatment of COPD. It was selected as a candidate for development from a well-understood class of drugs and is expected to enter the clinic in late 2008 (partnered with Dr Reddy's).


3. dAb - inhaled single domain antibody anti-inflammatory (partnered with Domantis, a subsidiary of GlaxoSmithKline).


4. LAMA - inhaled long-acting muscarinic (M3) receptor antagonists (partnered with AstraZeneca).


5. MABA - inhaled dual-acting muscarinic (M3) receptor antagonists / beta-2 receptor agonists (partnered with AstraZeneca).


6. ADC7828 - an inhaled elastase inhibitor, believed to be the first small molecule in this class for the treatment of CF and COPD. It is expected to enter the clinic in Q4 2009.


7. ADC3680 - an oral prostaglandin D2 (CRTh2) receptor antagonist for the treatment of allergic asthma and rhinitis. It is expected to enter the clinic in mid-2009.

For more information about collaboration opportunities in our respiratory programmes please contact us.

We are developing innovative therapies for COPD, Asthma and CF.

Download pipeline graphic (PDF)